UPDATE: AmpliPhi Biosciences (APHB) PT Lowered to $3.50 at H.C. Wainwright

(Updated - October 19, 2018 11:18 AM EDT)

(updated to add analyst comment)

H.C. Wainwright analyst Joseph Pantginis lowered the price target on AmpliPhi Biosciences (NYSE: APHB) to $3.50 (from $6.00) while maintaining a Buy rating.

Analyst comments: "Four way balancing act ongoing now. While the FDA discussions laid out important visibility, the company remains in a balancing act between several factors, data, regulatory, LPAD approval pathway potential, and funding. The company continues to broaden its efficacy database, as evidenced by the recent presentation at IDWeek. Further, the FDA visibility was an important deliverable, in our belief, but based on the current cash resources at the company (continued overhang), the company is assessing whether it might conduct one or more smaller studies in a highly focused population (e.g, LVAD or heart valve infection)."

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Boston Scientific (BSX) PT Raised to $83 at Stifel
• Amphenol (APH) PT Raised to $130 at Evercore ISI, Remains Top Pick
• Prudential Financial (PRU) PT Raised to $116 at Evercore ISI